Xgene Pharmaceutical Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $36.9M

  • Investors
  • 13

Xgene Pharmaceutical General Information

Description

Developer of innovative multimodal conjugated molecules designed to transform the treatment landscape of neurological disorders. The company's platform utilizes proprietary linker technology to generate dual-acting conjugates that combine therapeutic molecules, providing patients with non-opioid analgesic treatments that offer improved efficacy and reduced toxicity for neuropathic and nociceptive pain.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9F-13
  • No.188, Sec. 5, Nanjing E. Road, Shungshan Dist.
  • Taipei, 105
  • Taiwan
+886 02
Primary Industry
Drug Discovery
Corporate Office
  • 9F-13
  • No.188, Sec. 5, Nanjing E. Road, Shungshan Dist.
  • Taipei, 105
  • Taiwan
+886 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xgene Pharmaceutical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series D) 28-Jul-2026 $36.9M Completed Generating Revenue
4. Later Stage VC (Series C) 04-Nov-2021 Completed Generating Revenue
3. Early Stage VC (Series B1) 04-May-2019 Completed Generating Revenue
2. Early Stage VC (Series B) 23-Oct-2018 $20M $20M Completed Generating Revenue
1. Early Stage VC (Series A) 01-Mar-2016 Completed Generating Revenue
To view Xgene Pharmaceutical’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Xgene Pharmaceutical Patents

Xgene Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026194901-A1 Naproxen/pregabalin conjugate tablet formulation Pending 18-Mar-2025
WO-2026035552-A1 Naproxen/pregabalin conjugate dosing regimen Pending 05-Aug-2024
AU-2025276373-A1 Method of treating pain using topical naproxen and pregabalin conjugate formulations Pending 29-May-2024
WO-2025250613-A1 Method of treating pain using topical naproxen and pregabalin conjugate formulations Pending 29-May-2024
WO-2025064492-A1 Trpm8 antagonist for treating cancer Inactive 19-Sep-2023 A61K31/501
To view Xgene Pharmaceutical’s complete patent history, request access »

Xgene Pharmaceutical Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Shenzhen GTJA Investment Group Venture Capital Minority
Shenzhen Yifeng Investment Management Enterprise Venture Capital Minority
CITIC Securities Investment Bank Minority
Daoyuan Capital Venture Capital Minority
GSR United Capital Growth/Expansion Minority
You’re viewing 5 of 13 investors. Get the full list »

Xgene Pharmaceutical FAQs

  • When was Xgene Pharmaceutical founded?

    Xgene Pharmaceutical was founded in 2015.

  • Where is Xgene Pharmaceutical headquartered?

    Xgene Pharmaceutical is headquartered in Taipei, Taiwan.

  • What industry is Xgene Pharmaceutical in?

    Xgene Pharmaceutical’s primary industry is Drug Discovery.

  • Is Xgene Pharmaceutical a private or public company?

    Xgene Pharmaceutical is a Private company.

  • What is Xgene Pharmaceutical’s current revenue?

    The current revenue for Xgene Pharmaceutical is .

  • How much funding has Xgene Pharmaceutical raised over time?

    Xgene Pharmaceutical has raised $96.9M.

  • Who are Xgene Pharmaceutical’s investors?

    Shenzhen GTJA Investment Group, Shenzhen Yifeng Investment Management Enterprise, CITIC Securities, Daoyuan Capital, and GSR United Capital are 5 of 13 investors who have invested in Xgene Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process